Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.

BMC Cancer
Yumi AsukaiTatiana Dilla

Abstract

The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared with docetaxel. Costs were collected from the Spanish healthcare perspective. Outcomes of the model included total costs, total quality-adjusted life years (QALYs), total life years gained (LYG) and total progression-free survival (PFS). Mean survival was 1.03 years for the pemetrexed arm and 0.89 years in the docetaxel arm; QALYs were 0.52 compared to 0.42. Per-patient lifetime costs were 34677 euros and 32343 euros, respectively. Incremental cost-effectiveness ratios were 23967 euros per QALY gained and 17225 euros per LYG. Pemetrexed as a second-line treatment option...Continue Reading

References

May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Natasha B LeighlPamela J Goodwin
Jul 13, 2002·Gaceta sanitaria·J A SacristánJ L Pinto
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 24, 2005·Mayo Clinic Proceedings·Mical Paul, Leonard Leibovici
Oct 1, 2005·Archivos de bronconeumología·M A Alonso-FernándezUNKNOWN Grupo ASTURPAR (Sociedad Asturiana de Patología del Aparato Respiratorio) del Cáncer del Pulmón (GACP)
Jun 24, 2006·Journal of Pain and Symptom Management·Xavier Gómez-BatisteUNKNOWN Grupo de Evaluación-SECPAL
Nov 28, 2006·Archivos de bronconeumología·Ignacio Sánchez HernándezCarlos Almonacid Sánchez
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 26, 2008·Archivos de bronconeumología·Aurelio CayuelaRemedios Otero
Apr 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Cesare GridelliFilippo De Marinis
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Oct 23, 2008·Health and Quality of Life Outcomes·Beenish NafeesJessamy Watkins
Sep 3, 2009·Current Medical Research and Opinion·José Ignacio MayordomoUNKNOWN ENIA Study Group

❮ Previous
Next ❯

Citations

Jan 27, 2011·Current Treatment Options in Oncology·Linda E Coate, Natasha B Leighl
Nov 28, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Angel Sanz-GrandaJoan Rovira
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Yixing JiangChandra P Belani
Sep 17, 2013·Journal of Medical Economics·Anuraag R KansalSonja V Sorensen
Dec 20, 2012·Expert Review of Anticancer Therapy·Navneet SinghDigambar Behera
Sep 11, 2010·European Journal of Medicinal Chemistry·Khalid Mohammed Hassan HilmyAbd Almeneam el-Torgman
May 17, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takanori TsuchiyaKoichi Kawabuchi
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wieneke A BuikhuisenMarkus Joerger
Mar 18, 2015·Clinical Chemistry and Laboratory Medicine : CCLM·Naomi van der LindenCarin A Uyl-de Groot

❮ Previous
Next ❯

Software Mentioned

MS Excel

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Robert KleinLee Schwartzberg
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Robert KleinLee Schwartzberg
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Klazien Matter-WalstraMatthias Schwenkglenks
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Mark NuijtenUwe Siebert
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Josh J CarlsonDavid L Veenstra
© 2021 Meta ULC. All rights reserved